Compare · BDX vs VAPO
BDX vs VAPO
Side-by-side comparison of Becton Dickinson and Company (BDX) and Vapotherm Inc. (VAPO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and VAPO operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $52.78B, about 134.0x VAPO ($394.0M).
- BDX has hit the wire 8 times in the past 4 weeks while VAPO has been quiet.
- BDX has more recent analyst coverage (25 ratings vs 2 for VAPO).
- Company
- Becton Dickinson and Company
- Vapotherm Inc.
- Price
- $191.68-1.09%
- $1.25+21.95%
- Market cap
- $52.78B
- $394.0M
- 1M return
- +5.72%
- -
- 1Y return
- +0.32%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2018
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 2
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Vapotherm Inc.
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor, which provides compressed air necessary to run the precision flow systems; aerosol aeroneb adaptor to facilitate delivery of ultrasonic aerosolized medication; aerosol disposable patient circuit that is designed to streamline the provision of intermittent and continuous aerosol nebulization by limiting condensate management; and tracheostomy adaptors. In addition, Vapotherm, Inc. offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Modules, which helps clinicians maintain oxygen levels within a target range. The company sells its products to hospitals. Vapotherm, Inc. was founded in 1993 and is based in Exeter, New Hampshire.
Latest BDX
- BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026
- BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide
- BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results
- BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan
- BD Appoints Ferass Abuzaina as Worldwide President of Surgery
- BD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America's Healthcare Resilience
- EVP, Chief Revenue Officer Feld Michael sold $13,961 worth of shares (76 units at $183.70) as part of a pre-agreed trading plan, decreasing direct ownership by 0.39% to 19,644 units (SEC Form 4)
- BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
- Arthur Hu to Join BD as Chief Information and Digital Officer
- BD Advances Intelligent Robotics to Transform the Future of Pharmacy Care at Fairview
Latest VAPO
- CVRx Appoints John Landry as Chief Financial Officer
- SEC Form 15-12G filed by Vapotherm Inc.
- SEC Form EFFECT filed by Vapotherm Inc.
- SEC Form EFFECT filed by Vapotherm Inc.
- SEC Form EFFECT filed by Vapotherm Inc.
- Amendment: SEC Form SC 13D/A filed by Vapotherm Inc.
- Director Arnerich Anthony L. returned $344,305 worth of shares to the company (232,993 units at $1.48), closing all direct ownership in the company (SEC Form 4)
- President and CEO Army Joseph returned $43,419 worth of shares to the company (452,698 units at $0.10), closing all direct ownership in the company (SEC Form 4)
- SVP & Chief Financial Officer Landry John returned $51,982 worth of shares to the company (71,661 units at $0.73), closing all direct ownership in the company (SEC Form 4)
- SVP & Chief Technology Officer Lawrence Brian returned $81,355 worth of shares to the company (60,188 units at $1.35), closing all direct ownership in the company (SEC Form 4)